InvestmentUpdated on 18 June 2026
Investment opportunity in cannabis medicines for addiction treatment
CEO at MEDICAL FLOWERS DEVELOPMENTS
MADRID, Spain
About
MFD is preparing the clinical validation of a new generation of cannabis medicated chewing gums designed to support behavioural therapies in addiction treatment.
The first clinical program focuses on Cannabis Use Disorder (CUD), an unmet medical need with no approved pharmacological treatment today.
The product is conceived as a pharmaceutical-grade, single-dose oral dosage form with controlled delivery through the buccal mucosa. Its objective is to help manage anxiety peaks and craving during addiction treatment processes.
MFD is seeking biotech, pharma and health innovation investors to support its next value-inflection stage: Phase I clinical validation, regulatory development and preparation for future clinical expansion into other addiction-related indications, including alcohol, cocaine and opioid dependence.
Stage
- Seed and Development
Applies to
- Healthcare
Attached files
Organisation
Similar opportunities
Product
Cannabis medicated chewing gums for addiction treatment
- Health innovation
- Distribution Partner
- Pharmaceutical industry
David Molinero Caravantes
CEO at MEDICAL FLOWERS DEVELOPMENTS
MADRID, Spain
Project cooperation
Clinical and research collaborations in addiction treatment
- Planning
- Research
- Financing
David Molinero Caravantes
CEO at MEDICAL FLOWERS DEVELOPMENTS
MADRID, Spain
Partnership
Pharmaceutical partnerships for innovative addiction medicines
- Others
- Development
David Molinero Caravantes
CEO at MEDICAL FLOWERS DEVELOPMENTS
MADRID, Spain